Follow us on Twitter
twitter icon@FreshPatents


Cholesterol patents

      

This page is updated frequently with new Cholesterol-related patent applications.




 Compositions and therapeutic methods for accelerated plaque regression patent thumbnailnew patent Compositions and therapeutic methods for accelerated plaque regression
The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of formula i or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin..
Resverlogix Corp


 Use of quaternary pyridinium salts as vasoprotective agents patent thumbnailnew patent Use of quaternary pyridinium salts as vasoprotective agents
Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .

 Endoxifen compositions and methods patent thumbnailnew patent Endoxifen compositions and methods
The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, z- and e-guggulsterones, phospholipids, fatty acids, vitamin d, and vitamin e.
Jina Pharmaceuticals, Inc.


 Ketohexokinase (khk) irna compositions and methods of use thereof patent thumbnailKetohexokinase (khk) irna compositions and methods of use thereof
The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.


 Liposome comprising at least one cholesterol derivative patent thumbnailLiposome comprising at least one cholesterol derivative
More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.. .

 Antidiabetic compounds patent thumbnailAntidiabetic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Michael Miller


 Process for producing 7-dehydrocholesterol and vitamin d3 patent thumbnailProcess for producing 7-dehydrocholesterol and vitamin d3
According to the present invention, there can be provided a process for producing 7-dehydrocholesterol (hereinafter, “7dhc”), comprising culturing, in a medium, a 7dhc-producing labyrinthulea microorganism in which the 7dhc reducing activity is reduced or lost as compared to a parent strain through deletion, substitution, or addition of at least one base in a gene which is present in the chromosomal dna of the parent strain and encodes a protein having 7dhc reducing activity, and the microorganism produces 7dhc, allowing 7dhc to be produced and accumulated in the culture, and collecting the 7dhc from the culture; and a process for producing vitamin d3, comprising irradiating, with ultraviolet light, the 7dhc produced by the production process.. .
Kyowa Hakko Bio Co. Ltd.


 Shunting of dietary lipids including cholesterol patent thumbnailShunting of dietary lipids including cholesterol
Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body.
Boston Scientific Scimed, Inc.


 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects patent thumbnailMethods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania


 Cholesterol efflux capacity assessment patent thumbnailCholesterol efflux capacity assessment
A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) value. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics


Cholesterol efflux capacity assessment

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) level. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics Corporation

Measurement of serum lipoproteins

Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
Atherotech, Inc.

Process for refining chemicals from pulp and paper mill effluent

A process for isolating at least one target compound, such as manool, geranyl linalool, ethyl guaiacol, eugenol, veratraldehyde, squalene, terpin, cholesterol, beta-sitosterol, campesterol, stigmasterol, stigmastenol and dehydroabietic acid, from biomass, the process including steps of: obtaining a condensate from a recovery evaporator, a reverse osmosis retentate of a condensate of a pulp and paper mill, or both, the condensate, retentate or both being substantially free of higher molecular weight (approximately >1000 da) cellulose and/or lignin and/or lignin-derived material; optionally ph adjusting and filtering the condensate to collect insoluble material; extracting the condensate, the collected insoluble material, or both, with solid phase extraction (spe), liquid-liquid extraction or solid-liquid extraction to produce an extract containing the at least one target compound; and optionally purifying the extract containing the at least one target compound by thermal fractionation, chromatographic separation, recrystallization ion exchange, chelation, adsorption/desorption, lyophilization and sublimation or combinations thereof. The method is particularly useful for isolating the target compounds from wastewaters produced in a kraft pulp and paper mill, especially from recovery evaporator condensates produced during the treatment of black liquor..
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Environment

Mrna therapy for pompe disease

The present invention provides, among other things, methods of treating pompe disease, including administering to a subject in need of treatment a composition comprising an mrna encoding acid alpha-glucosidase (gaa) at an effective dose and an administration interval such that at least one symptom or feature of pompe disease is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids..
Shire Human Genetic Therapies, Inc.

Methods and creating particle derivatives of hdl with reduced lipid content

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of hdl without substantially affecting ldl. These derivatives of hdl are particles with reduced lipid content, particularly reduced cholesterol content.
Hdl Therapeutics

Method for pre-screening and correlation of underlying scarb1 gene variation to atherosclerosis in women and therapeutic use of progestational and other medications in treatment

A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the scarb1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.. .

Fasting mimicking and enhancing diet for treating hypertension and lipid disorders

Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated igf-1, elevated triglyceride levels, and/or elevated crp levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided.
University Of Southern California

Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein x is (ch2) or o, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis:. .
Merck Sharp & Dohme Corp.

Methods of sustaining dietary ketosis and its effects on lipid profile

The ketogenic diet (kd) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mm) without need for dietary restriction.
University Of South Florida

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.

Liposomal formulations for allosteric akt inhibitors

Disclosed herein is a lipid nanoparticle (lnp) composition comprising (a) an akt inhibitor; (b) dspc; (c) cholesterol; and (d) peg-dmg. Also disclosed herein is a method for preparing the lipid composition using a scalable tangential flow micro-mixing technology..
Merck Sharp & Dohme Corp.

Nanosomal preparation of the complex formed by quercetin (or another flavonol, flavone or a derivative thereof) and 2-hydroxypropyl-beta-cyclodextrin for intravenous use in cerebral pathological conditions

The invention involves the preparation of cholesterol lecithin nanosomes, without propylene glycol, from the complex formed by quercetin (or another flavonol or flavone or a derivative thereof) and 2-hydroxypropyl-β-cyclodextrin, by means of a process that allows the safe, effective intravenous use thereof in the treatment of cerebral pathological conditions in adults and newborns. The preparation is safe, stabilizes the altered haemodynamic parameters in severe neonatal hypoxia in newborn pigs and is effective in protecting cerebral function in experimental parkinson's disease models and in newborn pigs subject to hypoxia..

Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis

The described invention provides methods for targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.. .
Board Of Regents Of The University Of Texas System

Process for the preparation of colesevelam

The present invention relates to a new process for the synthesis of colesevelam, which is used in therapy in cases of hypercholesterolemia due to low density lipoproteins. Said process comprises the reaction, in a basic environment, of polyallylamine with: i) at least one alkylating agent of formula x—(ch2)9—ch3 and at least one alkylating agent of formula y—(ch2)6—n+ (ch3)3z−, wherein x and y are each independently a leaving group, and z is a halogen; and ii) at least one crosslinking agent.
Chemi Spa

Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport

The invention provides compositions and methods for assessing the capacity of high density lipoprotein (hdl) to support reverse cholesterol transport in blood by measuring exchange if hdl-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease.
Children's Hospital & Research Center At Oakland

Formulations for inhibition of pcsk9 for the treatment of hypercholesterolemia

Described herein are pharmaceutical formulations for the treatment of hypercholesterolemia, comprising nanoparticles having a polymeric hydrophobic core which is associated with an inhibitor of pcsk9. The inhibitor may be egf-a, egf-b, or an sirna.
Heart Biotech Limited

Means for lung specific delivery

The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (i) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, y′ is an anion, wherein each of r1 and r2 is individually and independently selected from the group consisting of linear c12-c18 alkyl and linear c12-c18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a pegylated lipid, wherein the pegylated lipid comprises a peg moiety and wherein the pegylated lipid is selected from the group consisting of a pegylated phosphoethanolamine of formula (ii) wherein each of r3 and r4 is individually and independently linear c13-c17 alkyl, and p is any integer from 15 to 130; a pegylated ceramide of formula (iii) wherein r5 is linear c7-c15 alkyl, and q is any integer from 15 to 130; and a pegylated diacylglycerol of formula (iv) wherein each of r6 and r7 is individually and independently linear c11-c17 alkyl, and r is any integer from 15 to 130.. .
Silence Therapeutics Gmbh

System and estimating low-density lippoprotein cholesterol from standard lipid profile

A system and method for estimating a cholesterol associated with low-density lipoprotein are provided. In one aspect, the method includes receiving a lipid profile of a subject, and identifying, from the lipid profile of the subject, a triglyceride concentration and a non-high-density lipoprotein cholesterol concentration.

Weight loss formulations, methods, and compositions based on traditional chinese medicine

The present invention relates to formulations made up from extracts from ganoderma lucidum, rhizome of coptis chinensis, radix astragali, nelumbo nucifera gaertn, chaenomeles speciosa, and fructus aurantii. Pursuant to the invention, the formulations are used to treat obesity and the biological sequelae of obesity including cholesterol levels and glucose levels.

Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile

A microorganism strain lactobacillus plantarum inducia dsm 21379 for use as hypocholesterolemic, antimicrobial and anti-oxidative agent and as enhancer of the natural defense potential of a subject. L.
Tervisliku Pllma Biotehnoloogiate Arenduskeskus OÜ (bio-competence Centre Of

Data collection and recommendation system

A data collection and recommendation system collect data and a recommendation is generated. The information collected may be, for example, data from patients getting general blood tests.

Composition comprising lactobacillus plantarum

The present invention relates to strain of lactobacilli and compositions containing the strain for use in modifying the absorption of cholesterol in an individual or the treatment of heart disease, diabetes or obesity.. .
Optibiotix Limited

Method of reducing employer health related costs while promoting employee wellness and health benefit plan strategy for same

In an effort to reduce employer health insurance related costs, at least one benefit under a health benefit plan is conditional on the employee voluntarily participating in a wellness program. The wellness program could include wellness categories such as a tobacco free category, normal blood pressure category, regular exercise category, a non-overweight category, a healthy cholesterol level category, a healthy blood glucose level category, and possibly even a category for participation in a health risk assessment.

Methods and device arrangement for physical activity thresholds promoting fat and cholesterol metabolism in high risk subjects

Method and device determine the threshold values for the volume and intensity of physical activity or the lowest levels that reduce risk factors in persons who suffer from disorders of sugar and lipid metabolism and are overweight. The method characterized in that the device registers a person's daily physical activity, compares it with the measured threshold levels and informs by its own or outside screen, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors.

Methods, compositions and kits for assaying mitochondrial function

The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., pfos) for measuring intracellular mitochondrial activity.. .
University Of Massachusetts

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Adjuvant compositions and related methods

The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide.
Vaxliant, Llc

Composition

The present invention relates to one or more strains of lactobacilli and a cholesterol modifying agent (such as an oilgosaccharide) for use in modifying the absorption of cholesterol in an individual or the treatment of heart disease, diabetes or obesity.. .
Optibiotix Limited

Modified irna agents

The invention relates to irna agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the irna agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety.
Alnylam Pharmaceuticals, Inc.

Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g.
Virginia Commonwealth University

Composition

The present invention relates to compositions for weight management comprising: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying component. The composition may also be used for the treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease..
Optibiotix Limited

Stable powder formulation containing an anticholingeric agent

A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which x− is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, to preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, α-hydroxycaprylic acid or gluconic acid.. .
Boehringer Ingelheim International Gmbh

Compositions and methods for cardiovascular disease

The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to reduce circulating levels of apob-100 or ldl.
The General Hospital Corporation





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8518

file did exist - 2686

0 - 1 - 54